For anyone following the search for drugs that clear aged cells: what a short course did in old mice, how a common gene variant in people fits in, and why it is no reason yet to change diet or supplements.
Senescent cells, the damaged cells that stop dividing and build up with age, turn out to run short of one particular fatty acid. When researchers gave that fatty acid back to cells in the lab, the senescent ones died. When they gave it by mouth to old mice, aged 22 to 24 months, markers of senescent cells fell in fat and liver within about three weeks. The study, led by Christopher Wiley at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, appeared online in Cell on 2 November.
What the cells were missing
The fatty acid is dihomo-gamma-linolenic acid, or DGLA, an omega-6 that sits midway on the chain the body uses to make arachidonic acid. The enzyme that turns DGLA into arachidonic acid is called delta-5 desaturase and is encoded by the FADS1 gene.
Senescent cells took up more of several polyunsaturated fatty acids than normal cells, yet their membranes held less DGLA. They also carried other features that make a cell prone to ferroptosis, an iron-dependent cell death driven by oxidised fats in the membrane: more free iron, more lipoxygenase enzymes and low-level membrane oxidation. Adding DGLA tipped them into ferroptosis. Blocking delta-5 desaturase did the same. According to the University of Eastern Finland, one of the participating institutions, healthy cells were largely spared.
What happened in old mice
Old mice received DGLA by mouth for five consecutive days and were examined two weeks later. In reporter mice that glow where the senescence gene p16 is active, the glow dropped. Staining for senescent cells was lower in fat and liver, and inflammatory signals typical of senescent cells fell in fat in both sexes.
Other changes were mostly seen in males. Old male mice had less liver scarring, lower levels of the liver enzyme AST, higher albumin, fewer clusters of inflammatory cells in the liver and lower blood urea, which the authors read as better kidney function. Female mice had almost no liver scarring to begin with, and their liver blood tests did not change. Not everything moved the right way: fat in the liver increased, which the authors suggest may be the extra DGLA being stored.
Lifespan was not measured, and neither were strength, endurance or frailty.
The human link
The team also used tissue from the Kuopio Obesity Surgery Study in Finland: fat samples from 185 people with obesity, 131 women and 54 men according to the 2024 preprint of the same work. In the women, and in all 185 people combined, a FADS1 variant that converts DGLA more slowly went with lower p21, a senescence marker, in fat. In the 54 men the same direction was not statistically significant. Another marker, p16, did not differ by genotype. This is an association in one group of people with obesity from a surgery study, not a test of DGLA as a treatment.
Why this is still far from people
The intervention evidence comes from cells and mice, after a short course and a two-week follow-up. The authors themselves write that clearing senescent cells by ferroptosis in living animals remains somewhat speculative, because DGLA has other effects in the body, including feeding anti-inflammatory signalling molecules. This study did not test safety or efficacy in people, and it gives no basis for changing diet or taking fatty-acid supplements. Anyone thinking about it should discuss it with their doctor.
Christopher Wiley is an inventor on patent applications on eliminating senescent cells with DGLA, delta-5 desaturase inhibitors and other ferroptosis inducers. The work was funded by the US Department of Agriculture, the US National Institute on Aging and private ageing-research foundations.
The search for drugs that remove senescent cells has so far produced clear results only in animals; a mineral salt that extended life in old male mice, reported earlier this month, is another example. What sets this study apart is a link to a natural genetic difference in people, which gives the idea a target worth testing.
Sources
Kuehnemann C, Jezak ST, Mogck BA, et al. Fatty acid desaturation controls cellular fate decisions between senescence and ferroptosis. Cell, online 2 November 2026. doi:10.1016/j.cell.2026.09.036, PubMed 42971201
Preprint of the same work: Kuehnemann C, et al. Fatty acid desaturation guides cellular decisions between ferroptosis and cellular senescence. bioRxiv, 3 October 2024, not peer reviewed. doi:10.1101/2024.10.03.616257
University of Eastern Finland. Fatty acid metabolism may help eliminate damaged and senescent cells. 3 November 2026. uef.fi
This article is for information only and does not replace a consultation with a doctor.
Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.
Read next
ResearchMedicine and treatmentA tau antibody missed its main Alzheimer's score
For anyone following Alzheimer's research: what a phase 2 trial found on the score clinicians use to track daily function, and which questions that result leaves open.
ResearchMedicine and treatmentEarly TB treatment and an esophageal cancer drug — plus 2 stories
4 stories this week: severe pneumonia in infants with HIV, esophageal cancer after a first treatment line, blood pressure and memory in type 2 diabetes, and a heart-rhythm ablation. Each note names who was studied and where the result stops.
Digest · 4 stories
ResearchMedicine and treatmentThe busiest minute of the day lined up with fewer deaths
For a reader who already moves on ordinary days and still cannot tell which part of that day is worth a conversation with a doctor. Inside is a comparison of people as they already were, not a plan for the next week.
